Trial reportPsychopharmacology2021
The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
Trial report in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype.Psychopharmacology · 2024Trial
- Longitudinal associations between binge drinking and changes in behavioral and neural threat reactivity in youth.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases.Biomedicines · 2026Review
- Sex-specific single transcript level atlas of vasopressin and its receptor (AVPR1a) in the mouse brain.eLife · 2026Article
- Reply to Lago, T.R.; Bolognani, F. Comment on "Nazarloo et al. Oxytocin, Vasopressin and Stress: A Hormetic Perspective.Current issues in molecular biology · 2026Article
- Comment on Nazarloo et al. Oxytocin, Vasopressin and Stress: A Hormetic Perspective.Current issues in molecular biology · 2026Article
- Neuropeptidergic systems in psychiatric disorders.Frontiers in endocrinology · 2025Review
- Future Directions in Anxiolytic Therapy: A Comprehensive Review of Novel Targets and Strategies.Current neurovascular research · 2025Review
- Discovery and evaluation of a novelActa pharmaceutica Sinica. B · 2024Article
- Validity of mental and physical stress models.Neuroscience and biobehavioral reviews · 2024Review
- The central renin-angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Review
- Effects of Icariin and Its Metabolites on GPCR Regulation and MK-801-Induced Schizophrenia-Like Behaviors in Mice.Molecules (Basel, Switzerland) · 2023Article
- Vasopressin as Possible Treatment Option in Autism Spectrum Disorder.Biomedicines · 2023Review
- Pharmacological properties and underlying mechanisms of aurantio‑obtusin (Review).Experimental and therapeutic medicine · 2023Review
- A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.Contemporary clinical trials communications · 2023Article
- Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder.Neuropharmacology · 2023Review
- Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment.Frontiers in neuroscience · 2023Review
- Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
rationaleArginine vasopressin (AVP) is a neuropeptide that modulates both physiological and emotional responses to threat. Until recently, drugs that target vasopressin receptors (V1a) in the human central nervous system were unavailable. The development of a novel V1a receptor antagonist, SRX246, permits the experimental validation of vasopressin's role in the regulation of anxiety and fear in humans.
objectivesHere, we examined the effects of SRX246 in a proof-of-concept translational paradigm of fear (phasic response to imminent threat) and anxiety (prolonged response to potential threat).
methodsHealthy volunteers received both SRX246 and placebo in a randomized, double-blind, counter-balanced order separated by a 5-7-day wash-out period. Threat consisted of unpleasant electric shocks. The "NPU" threat test probed startle reactivity during predictable threat (i.e., fear-potentiated startle) and unpredictable threat (i.e., anxiety-potentiated startle).
resultsAs predicted, SRX246 decreased anxiety-potentiated startle independent of fear-potentiated startle.
conclusionsAs anxiety-potentiated startle is elevated in anxiety and trauma-associated disorders and decreased by traditional anxiolytics such as SSRIs and benzodiazepines, the V1a receptor is a promising novel treatment target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.